| Bioactivity | YIAD-0205 is an orally available Aβ(1?42) aggregation inhibitor. YIAD-0205 demonstrated in vivo efficacy in an AD transgenic mouse model with five familial AD mutations (5XFAD)[1]. |
| Invitro | YIAD-0205（10 μM, 100 μM）抑制 Aβ (1?42) 聚集[1]。 0 --> YIAD-0205 相关抗体: |
| In Vivo | YIAD-0205（50 mg/kg；口服；每周两次，持续一个月）可降低 6.0 个月大的 5XFAD 小鼠模型中 Aβ 斑块和 Aβ 寡聚物的水平[1]。 |
| Name | YIAD-0205 |
| CAS | 2446054-34-6 |
| Formula | C26H16Br2ClN3 |
| Molar Mass | 565.69 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Cha M, et al. Benzo [d] imidazole-pyrrolo [1, 2-a] pyrazine Hybrids Ameliorate Amyloid Aggregates in the Brain of Alzheimer Transgenic Mice[J]. ACS Chemical Neuroscience, 2023, 14(17): 3025-3034... |
YIAD-0205
CAS: 2446054-34-6 F: C26H16Br2ClN3 W: 565.69
YIAD-0205 is an orally available Aβ(1?42) aggregation inhibitor. YIAD-0205 demonstrated in vivo efficacy in an AD trans
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.